SecBot SecBot
8-K ·Filed Apr 28, 2026
RC

RCKTW

ROCKET PHARMACEUTICALS, INC.
BULLISH
Impact 8/10
Horizonimmediate Processed6mo ago SEC0001140361-26-017275
8-K material event: Items 1.01
Actionable Insight ▲ Bullish

The $180M sale is a significant positive catalyst for RCKTW given the tiny market cap (~$1M). Monitor HSR clearance and closing. If completed, expect a sharp re-rating as cash balances will vastly exceed current market cap.

DirectionBullish
Confidencehigh
Horizonimmediate

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.0193
T+0 close · Apr 28, 2026 · via day close
Latest settled
−86.01%
T+60 · $0.002700
Vs SPY
−90.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $0.0193entry
  2. T+1 · 7mo ago 0.00%α +0.01% · $0.0193
  3. T+5 · 7mo ago 0.00%α −1.69% · $0.0193
  4. T+20 · 6mo ago 0.00%α −5.46% · $0.0193
  5. T+60 · 4mo ago −86.01%α −90.00% · $0.002700

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in cash, providing non-dilutive capital that extends the company's cash runway into the second quarter of 2028. This strengthens the balance sheet and supports advancement of its cardiovascular gene therapy pipeline.

Key Financial Metrics

Deal Value
$180.0M

Key Facts

  • Sold Rare Pediatric Disease Priority Review Voucher for $180 million in cash
  • Proceeds are non-dilutive and expected to extend cash runway into Q2 2028
  • Transaction subject to HSR waiting period expiration or termination
  • PRV was awarded from FDA accelerated approval of KRESLADI (marnetegragene autotemcel)

Financial Impact

$180 million cash inflow, extending cash runway into Q2 2028

cashcash runway

Risk Factors

  • Transaction may not close due to HSR or other conditions
  • Proceeds do not guarantee success of pipeline programs

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-017275
Document: ef20071574_ex99-1.htm0001140361-26-017275
Document: 0001140361-26-017275-index-headers.html0001140361-26-017275
Document: 0001140361-26-017275-index.html0001140361-26-017275
Document: 0001140361-26-017275.txt0001140361-26-017275

Track record

4 reports on RCKTW

Performance horizon
Filters
  1. May 13, 202626w ago 144 Neutral 2/10 Entry $0.0193 No price data
  2. May 7, 202627w ago 8-K Mixed 6/10 Entry $0.0193 to $0.001800 ▼ −90.67% −95.51% vs SPY
  3. May 7, 202627w ago 144 Neutral 3/10 Entry $0.0193 to $0.003200 ▼ −83.42% −87.25% vs SPY
  4. Apr 28, 202628w ago 8-K Bullish 8/10 Viewing Entry $0.0193 to $0.002700 ▼ −86.01% −90.00% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 6h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 28, 2026